Study Evaluating MST-997 in Advanced Malignant Solid Tumors

Summary

The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in Intralipid 20% administered on a weekly schedule to subjects with advanced malignant solid tumors.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications